April 15, 2024 at 05:00PM General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry

This guidance is intended to assist sponsors of investigational new drug applications (INDs) and applicants of new drug applications (NDAs), biologics license applications (BLAs), and supplements to such applications who are planning to conduct clinical studies in neonatal populations.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/05AcFuh